LLY logo

LLYLilly(Eli) & Co

$1,155.83
$17.73
(1.57%)
Today
Closed $1,149.15
$6.68
(0.58%)
After Hours
Updated: 05:21 PM EDT
EarningsAug 5
Mkt Cap$1.07T
Vol4.49M
News
all
press releases
LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in three late-stage trials.
Stocktwits
News Placeholder
More News
News Placeholder
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials PR Newswire INDIANAPOLIS, June 8, 2026...
PR Newswire
News Placeholder
Jim Cramer says he can't sell Eli Lilly despite its massive run up. Here's why
"I think the majority view is that Lilly is pulling away, kind of Secretariat-like," Jim Cramer said Monday...
CNBC: Healthcare
News Placeholder
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.
Key PointsZealand Pharma reported a high drop-out rate in a phase III trial of Survodutide, due to undesirable side effects experienced by patients...
Nasdaq News: Markets
News Placeholder
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?
ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.
Zacks
News Placeholder
ALT and the Rise of Dual Agonists Targeting Liver Disease
Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.
Zacks
News Placeholder
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.
Zacks
News Placeholder
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.
Zacks
News Placeholder
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.
Zacks
News Placeholder
Zacks Investment Ideas feature highlights: Eli Lilly and Merck
Health care's seasonal strength and defensive appeal are in focus, with Eli Lilly's growth and Merck's pipeline progress highlighted as key drivers.
Zacks
<
1
2
...
>

Advertisement|Remove ads.